Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of ucb 44212 as add-on therapy in subjects
 with focal epilepsy.
Inclusion Criteria:

 -  Males/Females from 18 to 65 years of age (minimum body weight of 40 kg)

 -  Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures
 whether or not secondarily generalized.

 -  Subjects who have been treated for epilepsy for ≥6 months and are currently
 uncontrolled while being treated with 1-3 concomitant AED(s), inclusive of LEV.

 -  Female subjects without childbearing potential or those who are using an acceptable
 contraceptive method

 Exclusion Criteria:

 -  Seizures occurring in clusters. Status epilepticus within 6 months of Visit 1. History
 of non-epileptic seizures

 -  Subjects on vigabatrin

 -  Subjects on felbamate, unless treatment has been continuous for >2 years

 -  Ongoing psychiatric disease other than mild controlled disorders.

 -  Subjects with clinically significant organ dysfunction

 -  Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients

 -  Pregnant or lactating women.

 -  Use of benzodiazepines (for any indication) taken at a higher frequency than an
 average of once a week, unless counted as one of the concomitant AEDs.